METHOD FOR PREDICTING TUMOUR RESISTANCE TO TETHEGETH THERAPY OF CETUXIMAB IN PATIENTS WITH PLANE-CELLULAR LANGUAGE OF LANGUAGE AND MULTIDISAL BOTTOM OF THE PTA Russian patent published in 2017 - IPC G01N33/48 G01N33/574 

FIELD: medicine.

SUBSTANCE: invention is a method for predicting tumour resistance to target therapy of cetuximab in patients with squamous cell carcinoma of the tongue and oral mucosa including a blood test, characterized in that two days before the initiation of a chemo-chemotherapy treatment with the inclusion of targeted cetuximab therapy in a patient with squamous cell carcinoma of the tongue And the mucosal bottom is determined by EGF, sEGFR, then the ratio of EGF/sEGFR is calculated and at a value of this ratio between 55.3-66.9 it is predicted that there is no resistance against Plaques to cetuximab therapy, and with the value of this indicator within 92.6-117.8 predict the presence of tumour resistance to cetuximab therapy.

EFFECT: early prognosis of tumour resistance to targeted therapy with cetuximab.

2 ex, 1 tbl